What are GnRH receptor antagonist drugs?

GnRH receptor antagonist drugs are pharmacologic agents that share a common mechanism (typically targeting GnRH receptor). 0 are currently marketed, with 3 more in clinical development.

GnRH receptor antagonist

0 marketed 2 in Phase 3 1 in Phase 2

This page covers all GnRH receptor antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting GnRH receptor.

Targets

GnRH receptor

Phase 3 pipeline (2)

Relugolix CT · University of Michigan · Oncology
Relugolix CT works by inhibiting the activity of gonadotropin-releasing hormone (GnRH) receptors.
Relugolix Combination Tablet · Sumitomo Pharma Switzerland GmbH · Oncology
Relugolix combination tablet works by inhibiting gonadotropin-releasing hormone (GnRH) receptors, leading to a decrease in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) production, which in turn reduces testosterone levels.

Phase 2 pipeline (1)

Degarelix & Relugolix · VA Office of Research and Development · Oncology
Degarelix and Relugolix are GnRH receptor antagonists that inhibit the production of gonadotropin-releasing hormone, leading to a decrease in testosterone levels.